Core Viewpoint - The company TianKang (301263.SZ) has received a notice of acceptance for the drug registration application of Safinamide Mesylate Tablets from the National Medical Products Administration (NMPA) in China, indicating progress in its drug approval process [1] Group 1: Company Developments - TianKang's wholly-owned subsidiary, Anhui TianKang Pharmaceutical Co., Ltd., has recently received the acceptance notice for the drug registration application [1] - The acceptance of the application is based on the review conducted by the NMPA according to Article 32 of the Administrative Licensing Law of the People's Republic of China [1] Group 2: Product Information - Safinamide Mesylate Tablets are a selective inhibitor of monoamine oxidase B (MAO-B) and are primarily used for treating adult patients with idiopathic Parkinson's disease (PD) [1] - The drug serves as an adjunct therapy to stable doses of Levodopa (L-dopa) alone or in combination with other PD treatments for patients experiencing mid to late-stage fluctuations [1]
泰恩康(301263.SZ)：甲磺酸沙非胺片药品注册上市许可申请获受理